Why Some IBD Treatments Don't Work: A Multi-Omics Study
Treatments studied
Part of Digestive system clinical trials.
This study looks at why some people with inflammatory bowel disease (Crohn's or ulcerative colitis) do not respond to certain biologic treatments. Researchers will use advanced testing (multi-omics) to better understand treatment response. If you are starting or have just started treatment with infliximab, adalimumab, vedolizumab, or ustekinumab, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with inflammatory bowel disease (Crohn's disease or ulcerative colitis).
- You are about to start or have started treatment with one of these medications: infliximab, adalimumab, vedolizumab, or ustekinumab. (Being on it for less than 3 months is okay.)
- You are not currently taking antibiotics, and you haven't taken antibiotics or probiotics in the past month.
- You do not have any other active autoimmune diseases (like lupus or rheumatoid arthritis) or an active tumor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at different ways to measure the amount of biologic drugs in your blood. It is for people with inflammatory bowel disease who are about to start a new biologic therapy or have never taken one before.
This study looks at people with active Crohn's disease or ulcerative colitis starting a new type of medication (anti-TNF, ustekinumab, upadacitinib, or vedolizumab), as well as people without IBD having a routine colonoscopy. It aims to collect information to better understand how these treatments work.
This study compares intravenous (IV) and under-the-skin (subcutaneous) biologic drugs for people with Crohn's disease or ulcerative colitis. It helps doctors understand if switching from the IV form to a shot is as effective and well-tolerated.
This study compares an existing UC medication (infliximab) with a newer one (ustekinumab) and a combination of both. The goal is to see which works best for moderate to severe UC when other treatments have failed.
This study is for children and teens with inflammatory bowel disease (Crohn's, colitis, or indeterminate) whose previous anti-TNF medicine stopped working. It compares several newer treatments to see which works best.
This study looks at what factors help predict how inflammatory bowel disease (IBD) may progress over time. You may be able to join if you are an adult with IBD and fit one of the study groups based on whether you have used TNF-blocking medicines before.
Hear when a new Inflammatory Bowel Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.